Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Anxiety Sensitivity Treatment for Heroin Users (ASTH-HR)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by University of Maryland.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Maryland
ClinicalTrials.gov Identifier:
NCT01196312
First received: August 23, 2010
Last updated: September 3, 2010
Last verified: September 2010

August 23, 2010
September 3, 2010
October 2009
March 2011   (final data collection date for primary outcome measure)
Anxiety Sensitivity Index-3 [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01196312 on ClinicalTrials.gov Archive Site
Timeline Follow Back 90 days [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Anxiety Sensitivity Treatment for Heroin Users
Novel Intervention for Drug Use and HIV Risk Among Anxiety Sensitive Heroin Users

Anxiety Sensitivity Treatment for Heroin Users is a development project targeting mild and above levels of anxiety sensitivity that will involve the testing of a specialized protocol for improving treatment retention and outcomes for heroin dependent individuals in a residential substance use treatment. ASTH-HR will integrate established treatment modules such as Healthy Relationships, along with interoceptive exposure, affect management, and psycho-education exercises developed for anxiety prevention and treatment programs with standard substance use treatment.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Anxiety
Behavioral: Anxiety sensitivity therapy
ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
September 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • exhibit a score of 21 on a self-report measure of anxiety sensitivity
  • be in 28 days of residential substance use treatment.
  • meet criteria for current opioid dependence as determined by SCID interview administered at intake.

Exclusion Criteria:

  • evidence of limited mental competency
  • the inability to give informed, voluntary, written consent to participate
  • current psychosis
  • current bipolar disorder.
Both
18 Years to 65 Years
No
Contact: Carl W Lejuez, PhD (301)405-5932 clejuez@psyc.umd.edu
United States
 
NCT01196312
DA023384
Not Provided
Dr. Carl W. Lejuez, Department of Psychology University Of Maryland, College Park
University of Maryland
Not Provided
Not Provided
University of Maryland
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP